GRM1 and schizophrenia: With a new mGlu1 PAM in hand, we disclose the full characterization (molecular pharmacology, in vitro and in vivo DMPK, and behavioral)of VU6033685/BI1752, as well as more egregious AEs in both rats anddogs, casting a shadow on a promising schizophrenia target.